Veracyte Inc. reported second-quarter 2026 revenue of $150.3 million, a 15% year-over-year increase driven by robust demand for its cancer diagnostics portfolio. The genetic diagnostics company also raised its full-year 2026 sales guidance to $590 million–$596 million, surpassing the consensus estimate of $586.445 million and signaling stronger-than-expected commercial performance. This upward revision reflects management’s confidence in sustaining double-digit growth despite broader economic uncertainties.

The results were bolstered by a 19% year-over-year jump in testing revenue to $145.7 million, which accounted for the majority of total income. Testing volume increased by 14% to 48,389 tests, while total test volume rose 13% to 50,967. Decipher Prostate tests contributed $91.9 million in revenue, up 20%, with volume growing 17% to approximately 29,700 tests. Afirma tests generated $51.2 million, an 18% increase, supported by a 10% volume rise to roughly 18,600 tests. Product revenue grew 7% to $3.9 million, while biopharmaceutical and other revenue declined to $0.8 million due to restructuring proceedings involving Veracyte SAS.

Financial Performance and Margins

Profitability metrics improved significantly alongside top-line growth. GAAP net income reached $25.5 million, or 17.0% of revenue, compared to a net loss of $0.98 million in the same period last year. Adjusted EBITDA expanded by 23% to $44.0 million, representing 29.2% of revenue, up from 27.5% in Q2 2025. Non-GAAP gross margin widened to 75%, compared to 72% in the prior year quarter, reflecting operational efficiencies. Operating expenses totaled $85.6 million, down from $95.0 million in Q2 2025, although non-GAAP operating expenses grew 16% to $70.0 million as the company invested in scaling its global operations.

Strategic Launches and Outlook

Veracyte highlighted two key product launches during the quarter: the Prosigna Breast Test for early-stage hormone-receptor positive breast cancer patients in the U.S., and the TrueMRD Monitoring Test for muscle-invasive bladder cancer (MIBC). Notably, the company secured Medicare coverage for the TrueMRD Monitoring Test, marking the first such coverage decision for its whole-genome sequencing-based platform. These launches expand Veracyte’s ability to serve patients across the cancer care continuum.

Looking ahead, Veracyte raised its testing revenue guidance to $576 million–$582 million, implying 17%–18% growth, excluding contributions from recently launched tests. The company continues to expect an adjusted EBITDA margin greater than 26% for the full year. Cash generation remained strong, with $45.8 million produced from operations in Q2, ending the period with $485.2 million in cash, cash equivalents, and short-term investments. Marc Stapley, CEO, stated that these launches position the company well to deliver durable double-digit growth.

Veracyte Inc., a global cancer diagnostics company listed on the Nasdaq under the ticker symbol VCYT, announced it will participate in two major investor conferences in late summer and early autumn 2026. The engagements aim to provide investors with updates on the company’s business strategy and pipeline developments through scheduled fireside chats.

The first engagement is set for Tuesday, Aug. 11, at the Canaccord Genuity 46th Annual Growth Conference in Boston, MA. Veracyte representatives will take part in a fireside chat beginning at 10:30 a.m. Eastern Time. This event offers an early opportunity for stakeholders to engage with management ahead of the broader healthcare sector calendar.

Conference Schedule

The second appearance will occur at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, NY. The fireside chat is scheduled for Tuesday, Sep. 15, at 5:35 p.m. Eastern Time. These presentations are standard components of the company’s quarterly investor relations cycle, designed to maintain transparency with shareholders and analysts.

Live audio webcasts of both sessions will be streamed on Veracyte’s official investor relations website at http://investor.veracyte.com/events-presentations . For those unable to attend live, replays of the webcasts will remain available for 90 days following each broadcast. This extended availability ensures that institutional and retail investors can review the discussions at their convenience.

What the Numbers Show

While this announcement contains no financial metrics, the timing of these conferences aligns with typical periods when biotech and diagnostics firms update markets on clinical trial progress or commercial adoption rates. Veracyte’s portfolio includes key genomic tests such as the Afirma Genomic Sequencing Classifier, Decipher Bladder and Prostate Genomic Classifiers, Prosigna Breast Risk of Recurrence test, and TrueMRD Monitoring Test for MIBC. Investor sentiment during these calls often hinges on commentary regarding reimbursement landscapes and hospital uptake for these specific assays.